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Arthroplasty registries play a critical role in improving the 
outcome of joint replacement surgery. They provide unique 
community-based  comparative  data  that  enables  individual 
surgeons to identify best practice that is relevant to their own 
approach to arthroplasty surgery. Registries simultaneously 
compare the effect of multiple factors on the outcome of joint 
replacement, and through ongoing monitoring are also sensi-
tive to the impact of changing practice. The information they 
provide is known to change practice in a beneficial manner. 
There continues, however, to be an ongoing debate about the 
value of registry data. 
Traditionally,  the  value  of  clinical  information  has  been 
determined by its standing in the hierarchy of levels of clinical 
evidence. The underlying basis for this hierarchy is the abil-
ity of the data to establish causality with respect to outcome. 
This has been specifically linked to study design, with a ran-
domized controlled trial (RCT) being recognized as having 
the greatest capacity to achieve this. If the clinical evidence 
approach is used to categorize registry-derived data, there is 
no option other than to regard this information as coming from 
an observational study. As such, registry data would be con-
sidered as having lower value than an RCT or a systematic 
review of RCTs. This could be correct with respect to ability 
to establish causality. However, is this clinically relevant and 
is it the best approach to determine comparative value of infor-
mation obtained from registries and clinical trials? 
Clinical trials are designed to provide evidence to prove 
a hypothesis. Important in their design is the need to limit 
from the outset the number of confounding factors that may 
have an impact on data analysis and its subsequent interpre-
tation.  Study  design  predetermines  where  the  trial  will  be 
undertaken, the surgeons involved, and which patients will be 
included, as well as the surgical technique and the prostheses 
to be used. Critical to the design is ensuring that the trial is 
adequately powered to enable statistical difference for the rel-
evant parameter(s) to be compared. A trial has an end. When 
a trial is designed, it is necessary to make assumptions. The 
accuracy and relevance of those assumptions will affect the 
study design and will depend on available knowledge and the 
understanding of that knowledge by the designers of the trial. 
A registry is not a clinical trial, and establishing causality is 
not its focus. A registry is an ongoing quality assurance mech-
anism that is designed to identify and monitor differences in 
comparative outcomes within the community being surveyed. 
The community may be a specific region, an entire country, 
or even a number of countries combined. As registries have a 
different purpose, their approach to data collection and analy-
sis is entirely different from a clinical trial. They attempt to 
ensure that there are no exclusions. All hospitals, surgeons, 
patients,  surgical  techniques,  and  prostheses  are  included. 
Analyses are undertaken to identify different outcomes asso-
ciated with these and other factors. The analysis is reported 
for a defined period. A registry is ongoing, and as such is able 
to monitor changing practice and the impact of that change 
on outcome. When a difference is established, a registry will 
undertake subsequent analyses in an attempt to identify fac-
tors that may or may not be associated with that difference. 
This is not attempting to assign causality, but to provide addi-
tional information that enables surgeons to effectively use the 
data to guide their choice of treatment options. 
To optimize community outcomes of joint replacement sur-
gery, it is not necessary to know why there is a difference. 
Incremental improvement can be achieved by surgeons choos-
ing treatment options that have been identified as having better 
outcomes or alternatively avoiding those that have not. Those 
that attempt to rank the value of registry data with respect 
to the capacity to identify causality have entirely missed the 
point of the purpose of a registry and the approach it uses to 
achieve this. 
This  raises  the  question  of  how  registry  data  should  be 
valued. If it is felt important to rank against clinical trials, then 
criteria relevant to both should be used. Using new criteria that 
differ from the capacity to identify causality will significantly 
alter the perspective of relative value. Strong arguments could 
be made that registries have a greater capacity to provide new 
information, that the information they provide is more appli-
cable, and that their ability to bring about beneficial clinical 
change is greater. 
The  predetermined  limitations  imposed  by  trial  design, 
although necessary to establish causality, impede their ability 
to identify additional factors that may have the potential to 
influence outcome. This limitation does not occur with regis-
try data analysis. Consequently, the potential for registry anal-
ysis to identify factors that have not previously been known to 
be associated with a particular outcome must be greater. The 
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involved in registry analysis. Additionally, registries have the 
capacity to provide important information that could never be 
obtained through a clinical trial. This includes all community-
based comparative outcomes, as well as providing insight into 
broad-based issues such as the impact of clinical experience 
or surgical skill. 
In  order  to  establish  causality,  a  well-designed  clinical 
trial must have high internal validity. This is achieved at the 
expense of external validity. An important effect of this is the 
subsequent limitation of the wider applicability of the trial 
results. A clinical trial may answer a specific question, but as 
a consequence of limited surgeon involvement and a restricted 
patient population, there may be difficulty in extrapolating 
these findings to community practice in order to achieve a 
beneficial outcome. 
There are many other reasons why trials may have limited 
beneficial impact on the outcome of joint replacement in the 
community. These include, amongst others, non-availability 
of specific expertise and infrastructure used within the trial or 
a lack of relevance, particularly if the technology or approach 
has been superseded during the time it took to undertake the 
trial. 
Stakeholder participation is another, often poorly considered 
difference. It has the potential to affect in a major way the abil-
ity to bring about beneficial change. In a clinical trial, stake-
holders are limited to the surgeons, patients, and the prosthesis 
company involved. Registries, on the other hand, have very 
wide stakeholder involvement. Not only do they include all 
surgeons, patients, and companies but also hospitals and gov-
ernment within the community being surveyed. This greater 
participation results in broad-based data ownership. Change is 
more likely to occur if individual stakeholders are able to iden-
tify areas for potential improvement based on analysis of their 
own data. The implication of this is that a registry will have 
the most impact within the community contributing data. This 
may well be true, but it does not mean that the information 
provided by registries lacks relevance to other surgeons. On 
the contrary, registry reporting of community-based analysis 
has the utmost relevance to any individual surgeon’s practice. 
Wider access to registry reports is essential, and this is facili-
tated by publication in refereed journals. Using this approach 
to more widely disseminate registry analysis has the added 
benefit of ensuring the maintenance of reporting standards. 
It is not clear what is to be gained by attempting to rank 
and contrast the value of information obtained from registries 
against clinical trials, particularly if the criteria used to rank 
that information is not relevant to registry analysis. Registries 
and clinical trials are two entirely separate approaches to data 
collection and analysis. It would seem that a more sensible 
approach would be to develop new criteria that can be used to 
assess and compare the value of registry data in its own right. 
Just like clinical trials, registries are individual—each with 
their own strengths and weaknesses. The type, completeness, 
and coverage of data collected by a registry, its stage of devel-
opment, the strategies used for internal and external data vali-
dation, the approach to analysis, and—importantly—the issue 
being addressed by that analysis all contribute to the relative 
value of the data compared to other registry data. 
Clinical trials and registries provide different information. 
One is not better than the other. They are complementary, and 
each has an important role in ensuring improved outcome of 
joint replacement. That outcome will be enhanced not only 
through  a  better  understanding  of  the  differences  between 
clinical  trials  and  registries,  but  also  through  an  enhanced 
appreciation of the relevance and inherent value of the infor-
mation provided by both. 
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